Patents Examined by Cecilia M. Jaisle
  • Pyridazine compound and use thereof
    Patent number: 7956184
    Abstract: A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating compound (1) are provided.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: June 7, 2011
    Assignees: Gilead Sciences, Inc., K.U. Leuven Research & Development, Gerhard Puerstinger
    Inventors: Steven S. Bondy, David A. Oare, Winston C. Tse
  • Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
    Patent number: 7951805
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8, and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: May 31, 2011
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Rajender Kamboj, Zaihui Zhang, Jianmin Fu, Serguei Sviridov, Shaoyi Sun, Mehran Seid Bagherzadeh, Vandna Raina, Duanjie Hou, Sultan Chowdhury, Shifeng Liu, Vishnumurthy Kodumuru, Nagasree Chakka
  • 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors
    Patent number: 7947683
    Abstract: The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salt thereof: processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: May 24, 2011
    Assignee: Glaxo Group Limted
    Inventors: Giorgio Bonanomi, Anna Checchia, Elettra Fazzolari, Dieter Hamprecht, Fabrizio Micheli, Luca Tarsi, Silvia Terreni
  • Isoxazolo-pyridazine derivatives
    Patent number: 7943619
    Abstract: The invention relates to isoxazolo-pyridazine compounds, in particular those of formula I as described above and to a pharmaceutically acceptable salts thereof, having affinity and selectivity for the GABA A ?5 receptor binding site, their manufacture, pharmaceutical compositions containing them and their use as cognitive enhancers or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: May 17, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Roland Jakob-Roetne, Henner Knust, Andrew Thomas
  • Azaindoles for inhibiting aurora2 and other kinases
    Patent number: 7943616
    Abstract: The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: May 17, 2011
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Paul J. Cox, Tahir N. Majid, Justine Yeun Quai Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin, Charles J. Gardner, Dorothea Kominos, Brian L. Pedgrift, Frank Halley, Timothy A. Gillespy, Michael Edwards, Francois F. Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N. A. Bezard, Chantal Carrez
  • Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors
    Patent number: 7932253
    Abstract: N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-4-(6,9-difluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-benzamide is a CD80 antagonist, useful in the treatment of diseases which benefit from immuno-inhibition.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: April 26, 2011
    Assignee: MediGene AG
    Inventor: Ian Richard Matthews
  • Substituted 2,5-dihydro-3H-pyrazolo[4,3-C]pyridazin-3-one derivatives, preparation thereof and therapeutic use of the same
    Patent number: 7915258
    Abstract: The invention relates to compounds having the formula (I): Wherein R1, R2, R3 and R4 are as described herein. Also disclosed are the method of preparation and their use in therapy.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: March 29, 2011
    Assignee: Sanofi-Aventis
    Inventors: Christian Congy, Victor Dos Santos, Murielle Rinaldi-Carmona, Arnaud Rouquette, Didier Van Broeck
  • Anti-viral compounds
    Patent number: 7915411
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: March 29, 2011
    Assignee: Abbott Laboratories
    Inventors: David A. Betebenner, David A. DeGoey, Clarence J. Maring, Allan C. Krueger, Nobuhiko Iwasaki, Todd W. Rockway, Curt S. Cooper, David D. Anderson, Pamela L. Donner, Brian E. Green, Dale J. Kempf, Dachun Liu, Keith F. McDaniel, Darold L. Madigan, Christopher E. Motter, John K. Pratt, Jason P. Shanley, Michael D. Tufano, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu, David J. Grampovnik
  • Process for the synthesis of 9-hydroxy risperidone (paliperidone)
    Patent number: 7915412
    Abstract: The present invention relates to a process for preparing paliperidone from its intermediate 3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrrido[1,2-a]-pyrimidin-4-one.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: March 29, 2011
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Santiago Ini, Naama Chasid, Yaron Shmuely, Kobi Chen
  • Anti-viral compounds
    Patent number: 7910595
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: March 22, 2011
    Assignee: Abbott Laboratories
    Inventors: David A. Betebenner, David A. DeGoey, Clarence J. Maring, Allan C. Krueger, Nobuhiko Iwasaki, Todd W. Rockway, Curt S. Cooper, David D. Anderson, Pamela L. Donner, Brian E. Green, Dale J. Kempf, Dachun Liu, Keith F. McDaniel, Darold L. Madigan, Christopher E. Motter, John K. Pratt, Jason P. Shanley, Michael D. Tufano, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu, David J. Grampovnik
  • Synthesis of alkyl-capped alkoxylated esters useful as suds-controlling surfactants
    Patent number: 7910759
    Abstract: Alkyl-capped alkoxylated ester compounds of the formula wherein R1 is ethyl or butyl, R2 is linear or branched C16 to C18 hydrocarbon and x is greater than 3 to an n of 10.5 which are the reaction products of ethoxylating compounds of the formula R1O(CH2CH2O)nH that are free of ethylene glycol alkyl ether and diethyleneglycol alkyl ether. The ethoxylated reaction products are surfactants that exhibit suds controlling properties with various anionic surfactants.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: March 22, 2011
    Assignee: The Procter & Gamble Company
    Inventors: Lon Montgomery Gray, Jeffrey John Scheibel, Phillip Kyle Vinson, Christopher James Binski
  • Phthalazinone derivatives
    Patent number: 7902193
    Abstract: A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; D is selected from: (i) where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N; and (ii) where Q is O or S; RD is: wherein RN1 is selected from H and optionally substituted C1-10 alkyl; X is selected from a single bond, NRN2, CRC3RC4 and C?O; RN2 is selected from H and optionally substituted C1-10 alkyl; RC3 and RC4 are independently selected from H, R, C(?O)OR, where R is optionally substituted C1-10 alkyl, optionally substituted C5-20 aryl or optionally substituted C3-20 heterocyclyl; Y is selected from NRN3 and CRC1RC2.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: March 8, 2011
    Assignee: Maybridge Limited
    Inventors: Muhammad Hashim Javaid, Keith Allan Menear, Sylvie Gomez, Marc Geoffrey Hummersone, Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Xiao-Ling Fan Cockcroft, Frank Kerrigan
  • Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof
    Patent number: 7893259
    Abstract: The disclosure concerns pyrido[2,3-d]pyrimidine derivatives, their preparation and their therapeutic application, of general formula (I): and acid addition salts, hydrates and solvates thereof, as well as in the form of enantiomers, diastereoisomers and mixtures thereof. The disclosure also concerns methods for preparing said derivatives, pharmaceutical compositions containing a compound of general formula (I), and their therapeutic use.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: February 22, 2011
    Assignee: Sanofi-Aventis
    Inventors: Bernard Bourrie, Pierre Casellas, Samir Jegham, Pierre Perreaut
  • Heterocyclic derivatives
    Patent number: 7893073
    Abstract: The invention relates to novel 3,4-dihydropyrimidin-2(1H)-one derivatives having the formula processes for their preparation, and their use in compositions, and in the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.
    Type: Grant
    Filed: February 15, 2005
    Date of Patent: February 22, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Heike Gielen-Haertwig, Barbara Albrecht, Jörg Keldenich, Volkhart Li, Josef Pernerstorfer, Karl-Heinz Schlemmer, Leila Telan
  • Aza-benzothiophenyl compounds and methods of use
    Patent number: 7893085
    Abstract: The invention relates to azabenzothiophenyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzothiophenyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: February 22, 2011
    Assignee: Genentech, Inc
    Inventors: Pascal Pierre Savy, Stephen Price, Hazel Joan Dyke, John Gary Montana, Karen Williams, Mark S. Stanley, Liang Bao
  • Heterocyclic inhibitors of MEK and methods of use thereof
    Patent number: 7893065
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, and W are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative and inflammatory diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: February 22, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli M. Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • Oxazoloisoquinoline derivatives as thrombin receptor antagonists
    Patent number: 7888369
    Abstract: This application provides for oxazolisoquinoline derivatives of the formula or a pharmaceutically acceptable salt of said compound wherein: B is —CH?CH—; M is —C(R1)(R2)—; and the remaining substituents are as defined in the specification as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. This application also provides for combination therapy with the compounds of Ib or pharmaceutically acceptable salts thereof with other cardiovascular agents.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: February 15, 2011
    Assignee: Schering Corporation
    Inventors: Samuel Chackalamannil, Yuguang Wang
  • 6-substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors
    Patent number: 7879857
    Abstract: The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, R1, R2, R3, R4 and X have defined meanings.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: February 1, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Dominique Jean-Pierre Mabire, Jérôme Emile Georges Guillemont, Jacobus Alphonsus Josephus Van Dun, Maria Victorina Francisca Somers, Walter Boudewijn Leopold Wouters
  • Dipeptidyl Peptidase-IV inhibiting compounds, method of preparing the same, and pharmaceutical compositions containing the same as an active agent
    Patent number: 7879848
    Abstract: Novel compounds exhibiting good inhibitory activity versus Dipeptidyl Peptidase-IV(DPP-IV) include those of the following formula (1) or pharmaceutically acceptable salt thereof: wherein A is a substituted or unsubstituted 1,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine, 5,6 -dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine, 4,5-dihydro-7H-isooxazolo[3,4-c]pyridine, 3,4 -dihydroisoquinoline, 5,8-dihydropyrido[3,4-d]pyrimidine, or 6,7 -dihydro[1,3]thiazolo[4,5,c]pyridine, and B is a substituted or unsubstituted piperidin-2-one, morpholin-3-one, oxazolidin-2-one, pyrrolidin-2-one, or 1,5-dihydro-pyrrol-2-one. Methods of preparing the novel inhibitory compounds of formula (1) and pharmaceutical compositions containing the same as an active agent are disclosed.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: February 1, 2011
    Assignee: LG Life Sciences, Ltd.
    Inventors: Chang-Seok Lee, Jong Sung Koh, Ki Dong Koo, Geun Tae Kim, Kyoung-Hee Kim, Sang Yong Hong, Sungsub Kim, Min-Jung Kim, Hyeon Joo Yim, Dongchul Lim, Hye Jin Kim, Hee Oon Han, Seong Cheol Bu, Oh Hwan Kwon, Sung Ho Kim, Gwong-Cheung Hur, Ji Young Kim, Zi-Ho Yeom, Dong-Jun Yeo
  • Phthalazinones
    Patent number: 7875614
    Abstract: Compounds of the formula I, in which R, R1, R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3 and Y1 have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: January 25, 2011
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Dirk Finsinger, Kai Schiemann, Ulrich Emde, Frank Zenke, Christiane Amendt